Durvalumab is a type of immunotherapy and is known by its brand name, Imfinzi. Its role in treatment of small cell lung cancer is increasing. Durvalumab injection is injected into a vein over 60 minutes and is usually injected once every two weeks, once every three weeks or once every four weeks for as long as doctor recommends. The dosing schedule also depends on cancer type and how the body responds to the medication.
It is used alone to treat non-small cell lung cancer that has spread to nearby tissues and cannot be removed by surgery. It is also used in combination with platinum-based chemotherapy and Imjudo to treat a certain type of non-small cell lung cancer that has spread throughout the lungs and to other parts of the body as well. Its injection is also used in combination with chemotherapy agents to treat small cell lung cancer in adults.
Durvalumab has the capacity to prolong survival in people with advanced small cell lung cancer, according to the new results from clinical trail show. In this study, they combined treatment with Durvalumab to standard chemotherapy regimen to increase the overall survival rates in patients with newly diagnosed advanced small cell lung cancer by approximately three months in comparison to those with standard chemotherapy alone. Unfortunately, SCLC tends to spread, come back and when it comes back, it is less sensitive to subsequent chemotherapy.
Further studies are recommended to identify patients with small cell lung cancer who might derive long-term survival benefit from Durvalumab. There’s still lot of room for improvement in SCLC treatment and clinical trial strategies are coming through the pipeline.
The information shared in this blog is for educational purposes only. For any medical issues, you should always contact your healthcare provider.